Welcome to our dedicated page for Tonix Pharmaceut news (Ticker: TNXP), a resource for investors and traders seeking the latest updates and insights on Tonix Pharmaceut stock.
Tonix Pharmaceuticals Holding Corp. develops and commercializes biotechnology products for central nervous system disorders, immunology, infectious diseases and rare diseases. Company news centers on TONMYA, an FDA-approved cyclobenzaprine HCl sublingual tablet for fibromyalgia in adults, along with marketed acute migraine products Zembrace SymTouch and Tosymra.
Recurring updates also cover Tonix’s development pipeline, including TNX-4800, a long-acting anti-Borrelia OspA human monoclonal antibody for Lyme disease prophylaxis; TNX-1900 intranasal potentiated oxytocin for craniofacial pain conditions; TNX-1700 and TNX-4700 immuno-oncology programs; TNX-801 vaccine research; and TNX-1500 for prevention of kidney transplant rejection. Other company developments include scientific presentations, clinical and preclinical data, commercial access arrangements, operating results, capital-structure disclosures and governance matters.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Tonix Pharmaceuticals has introduced its new antidepressant candidate, TNX-601 ER (tianeptine hemioxalate), which may provide significant therapeutic advantages over current U.S. antidepressants. For over 30 years, tianeptine has been available outside the U.S. and is noted for its efficacy without causing sexual dysfunction or weight gain. This unique mechanism of action promotes neuron connectivity, potentially offering longer-term relief from depression. The company is conducting a Phase 2 study called UPLIFT to evaluate the safety of TNX-601 ER in ~300 patients, with results expected in Q4 2023. The global antidepressant market reached $15 billion in 2020 and is projected to grow to $21 billion by 2030, driven by innovative treatment options.
Tonix Pharmaceuticals (Nasdaq: TNXP) presented research on TNX-1700 at the AACR Annual Meeting (April 14-19, 2023). The studies demonstrated that mTNX-1700, a TFF2-albumin fusion peptide, effectively targeted myeloid-derived suppressor cells (MDSCs) and enhanced anti-tumor immunity when combined with PD-1 blockade therapy in mouse models of colorectal and gastric cancer.
The poster titled “MDSC-targeted TFF2-MSA suppresses tumor growth and increases survival in anti-PD-1 treated MC38 and CT26.wt murine colorectal cancer models” showed significant anti-tumor effects. Another poster focused on diffuse-type gastric cancer, suggesting the potential of mTNX-1700 in combination treatments.
CEO Seth Lederman stated that the results indicate mTNX-1700 offers additive benefits to existing cancer therapies, paving the way for future clinical exploration.